2022. The prospective randomized trial evaluating the efficacy of the mitomycin C and cisplatin regimen (MP) versus standard first-line chemotherapy in patients with advanced BRCA1/2-associated ovarian cancer (NCT04747717). Voprosy onkologii. 68, 5 (Oct. 2022), 628–638. DOI:https://doi.org/10.37469/0507-3758-2022-68-5-628-638.